Quark, Pfizer Amend Deal for Ocular Disease Drug on Less-than-Ideal Phase II Data

The new deal shifts to Quark the responsibility for conducting a planned phase IIb study of the drug. It also gives Pfizer the opportunity to pull out of the partnership, depending on the outcome of the trial.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.